Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 343 participants.
Also called NCT01898221
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 343 participants
- Sponsor
- Registry
-
NCT01898221
-
- Other papers using this trial's data
- Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01898221. Randomized; single masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2019-12 (actual). Results posted on 2025-08-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation
- Acronym
- VOM-R01
- Condition
- Ventricular Tachycardia
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Ethanol
- Intervention (Procedure)
- Ablation
- Lead sponsor
- The Methodist Hospital Research Institute
- Collaborator
- National Institutes of Health (NIH)
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct01898221- Content hash
c6ce1d7c4d0067ea36455d23b9474ff72a0318955169d6ab1fc4c4ac0d87a9a3